Dystrotic epidermolysis bullosa (DEB)
About
DEB is caused by a mutation in the COL7A1 gene, resulting in a deficiency of type VII collagen, increased fragility of skin and mucous membranes, and slight friction can lead to blisters and erosion. Core dilemmas: ① Recurrent blisters, pain, and infections throughout life;② Chronic wounds can lead to squamous cell carcinoma;③ There is currently no cure;④ Although gene therapy (Vyjuvek) is approved, the price is extremely high.
Features & Symptoms
- COL7A1 gene mutation
- Type VII collagen deficiency
- Increased fragility of skin and mucous membranes
- Repeated blisters and erosion
Treatment Options
| Treatment | Description | Stage | Price Range |
|---|---|---|---|
| Beremagene geperpavec（Vyjuvek） | HSV-1 vector gene therapy, topical application, approved by the FDA in 2023, can promote wound healing. | FDA批准 | $1M - $2M/年 |
| Gene therapy (COL7A1) | Autologous keratinocytes were modified by retrovirus and transplanted and are currently in clinical trials. | Phase II | $500K - $1.5M/次 |
| Comprehensive wound care | Including comprehensive care plans such as sterile dressing, pain management, infection prevention, and nutritional support. | 临床应用 | $100K - $300K/年 |
Prognosis
Severe patients can die from infection or cancer, and mild patients can survive into adulthood
Additional Notes
Notes: Wound care: Standardized wound care is the core of management, and non-adhesive dressings and silicone gel dressings should be used; Cancer monitoring: Chronic wounds can lead to squamous cell carcinoma (SCC), and annual skin cancer screening is recommended; Nutritional support: Chronic wounds cause protein and heat loss, requiring nutritional evaluation and supplementation; Pain management: Chronic wound pain and dressing change pain are common and require standardized analgesia;Beremagene geperpavec: Local gene therapy approved for RDEB can promote wound healing.; Exclusive service commitment: The platform will allocate a dedicated medical team to each patient to assist in dismantling and properly deploying the following precautions throughout the process. When cross-state and cross-border diagnosis and treatment projects or drugs are involved, the platform will make overall arrangements for the entire docking; for disabled and semi-disabled patient groups, the platform will provide rush-free alternative solutions (including remote consultation, door-to-door sampling, direct drug delivery in the cold chain, etc.), to ensure that patients can get the same high-quality diagnosis and treatment resources without having to travel in person.; Study phase: FDA approval. Prognosis: Severe patients can die of infection or cancer, and mild patients can survive into adulthood.
Frequently Asked Questions
What is Dystrotic epidermolysis bullosa (DEB)?
DEB is caused by a mutation in the COL7A1 gene, resulting in a deficiency of type VII collagen, increased fragility of skin and mucous membranes, and slight friction can lead to blisters and erosion. Core dilemmas: ① Recurrent blisters, pain, and infections throughout life;② Chronic wounds can lead to squamous cell carcinoma;③ There is currently no cure;④ Although gene therapy (Vyjuvek) is approved, the price is extremely high.
What are the symptoms of Dystrotic epidermolysis bullosa (DEB)?
COL7A1 gene mutation,Type VII collagen deficiency,Increased fragility of skin and mucous membranes,Repeated blisters and erosion
How is Dystrotic epidermolysis bullosa (DEB) treated?
Beremagene geperpavec（Vyjuvek）: HSV-1 vector gene therapy, topical application, approved by the FDA in 2023, can promote wound healing.; Gene therapy (COL7A1): Autologous keratinocytes were modified by retrovirus and transplanted and are currently in clinical trials.; Comprehensive wound care: Including comprehensive care plans such as sterile dressing, pain management, infection prevention, and nutritional support.
What is the prognosis for Dystrotic epidermolysis bullosa (DEB)?
Severe patients can die from infection or cancer, and mild patients can survive into adulthood